Ataxin-1 regulates epithelial-mesenchymal transition of cervical cancer cells

A. Ram Kang, Hyoung Tae An, Je Sang Ko, Seong Man Kang

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The mutant form of the protein ataxin-1 (ATXN1) causes the neurodegenerative disease spinocerebellar ataxia type-1. Recently, ATXN1 was reported to enhance E-cadherin expression in the breast cancer cell line MCF-7, suggesting a potential association between ATXN1 and cancer development. In the present study, we discovered a novel mechanism through which ATXN1 regulates the epithelial- mesenchymal transition (EMT) of cancer cells. Hypoxia-induced upregulation of the Notch intracellular domain expression decreased ATXN1 expression via MDM2-associated ubiquitination and degradation. In cervical cancer cells, ATXN1 knockdown induced EMT by directly regulating Snail expression, leading to matrix metalloproteinase activation and the promotion of cell migration and invasion. These findings provide insights into a novel mechanism of tumorigenesis and will facilitate the development of new and more effective therapies for cancer.

Original languageEnglish
Pages (from-to)18248-18259
Number of pages12
JournalOncotarget
Volume8
Issue number11
DOIs
Publication statusPublished - 2017

Fingerprint

Epithelial-Mesenchymal Transition
Uterine Cervical Neoplasms
Spinocerebellar Ataxias
Neoplasms
Ubiquitination
Snails
Mutant Proteins
Cadherins
Matrix Metalloproteinases
Neurodegenerative Diseases
Cell Movement
Ataxin-1
Carcinogenesis
Up-Regulation
Breast Neoplasms
Cell Line

Keywords

  • ATXN1
  • Cervical cancer
  • Epithelial-mesenchymal transition
  • Notch intracellular domain

ASJC Scopus subject areas

  • Oncology

Cite this

Ataxin-1 regulates epithelial-mesenchymal transition of cervical cancer cells. / Kang, A. Ram; An, Hyoung Tae; Ko, Je Sang; Kang, Seong Man.

In: Oncotarget, Vol. 8, No. 11, 2017, p. 18248-18259.

Research output: Contribution to journalArticle

Kang, A. Ram ; An, Hyoung Tae ; Ko, Je Sang ; Kang, Seong Man. / Ataxin-1 regulates epithelial-mesenchymal transition of cervical cancer cells. In: Oncotarget. 2017 ; Vol. 8, No. 11. pp. 18248-18259.
@article{efe8e9cc876c4b00871d90caee06c687,
title = "Ataxin-1 regulates epithelial-mesenchymal transition of cervical cancer cells",
abstract = "The mutant form of the protein ataxin-1 (ATXN1) causes the neurodegenerative disease spinocerebellar ataxia type-1. Recently, ATXN1 was reported to enhance E-cadherin expression in the breast cancer cell line MCF-7, suggesting a potential association between ATXN1 and cancer development. In the present study, we discovered a novel mechanism through which ATXN1 regulates the epithelial- mesenchymal transition (EMT) of cancer cells. Hypoxia-induced upregulation of the Notch intracellular domain expression decreased ATXN1 expression via MDM2-associated ubiquitination and degradation. In cervical cancer cells, ATXN1 knockdown induced EMT by directly regulating Snail expression, leading to matrix metalloproteinase activation and the promotion of cell migration and invasion. These findings provide insights into a novel mechanism of tumorigenesis and will facilitate the development of new and more effective therapies for cancer.",
keywords = "ATXN1, Cervical cancer, Epithelial-mesenchymal transition, Notch intracellular domain",
author = "Kang, {A. Ram} and An, {Hyoung Tae} and Ko, {Je Sang} and Kang, {Seong Man}",
year = "2017",
doi = "10.18632/oncotarget.15319",
language = "English",
volume = "8",
pages = "18248--18259",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "11",

}

TY - JOUR

T1 - Ataxin-1 regulates epithelial-mesenchymal transition of cervical cancer cells

AU - Kang, A. Ram

AU - An, Hyoung Tae

AU - Ko, Je Sang

AU - Kang, Seong Man

PY - 2017

Y1 - 2017

N2 - The mutant form of the protein ataxin-1 (ATXN1) causes the neurodegenerative disease spinocerebellar ataxia type-1. Recently, ATXN1 was reported to enhance E-cadherin expression in the breast cancer cell line MCF-7, suggesting a potential association between ATXN1 and cancer development. In the present study, we discovered a novel mechanism through which ATXN1 regulates the epithelial- mesenchymal transition (EMT) of cancer cells. Hypoxia-induced upregulation of the Notch intracellular domain expression decreased ATXN1 expression via MDM2-associated ubiquitination and degradation. In cervical cancer cells, ATXN1 knockdown induced EMT by directly regulating Snail expression, leading to matrix metalloproteinase activation and the promotion of cell migration and invasion. These findings provide insights into a novel mechanism of tumorigenesis and will facilitate the development of new and more effective therapies for cancer.

AB - The mutant form of the protein ataxin-1 (ATXN1) causes the neurodegenerative disease spinocerebellar ataxia type-1. Recently, ATXN1 was reported to enhance E-cadherin expression in the breast cancer cell line MCF-7, suggesting a potential association between ATXN1 and cancer development. In the present study, we discovered a novel mechanism through which ATXN1 regulates the epithelial- mesenchymal transition (EMT) of cancer cells. Hypoxia-induced upregulation of the Notch intracellular domain expression decreased ATXN1 expression via MDM2-associated ubiquitination and degradation. In cervical cancer cells, ATXN1 knockdown induced EMT by directly regulating Snail expression, leading to matrix metalloproteinase activation and the promotion of cell migration and invasion. These findings provide insights into a novel mechanism of tumorigenesis and will facilitate the development of new and more effective therapies for cancer.

KW - ATXN1

KW - Cervical cancer

KW - Epithelial-mesenchymal transition

KW - Notch intracellular domain

UR - http://www.scopus.com/inward/record.url?scp=85015252775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015252775&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.15319

DO - 10.18632/oncotarget.15319

M3 - Article

AN - SCOPUS:85015252775

VL - 8

SP - 18248

EP - 18259

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 11

ER -